Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | FLT3 |
Variant | F594_W603dup |
Impact List | duplication |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | FLT3 F594_W603dup indicates the insertion of eight duplicate amino acids, aspartic acid (D)-593 through tryptophan (W)-603, in the juxtamembrane domain of the Flt3 protein (PMID: 14759363). FLT3 F594_W603dup has not been biochemically characterized, but can be predicted to lead to activation of Flt3 based on the effects of other Flt3 internal tandem duplication (ITD) mutations (PMID: 12970773, PMID: 9737679, PMID: 11090077). |
Associated Drug Resistance | |
Category Variants Paths |
FLT3 mutant FLT3 act mut FLT3 exon 14 ins FLT3 F594_W603dup FLT3 mutant FLT3 exon14 FLT3 exon 14 ins FLT3 F594_W603dup |
Transcript | NM_004119.3 |
gDNA | chr13:g.28034110_28034139 |
cDNA | c.1780_1809 |
Protein | p.F594_W603 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_004119.3 | chr13:g.28034110_28034139 | c.1780_1809 | p.F594_W603 | RefSeq | GRCh38/hg38 |
NM_004119 | chr13:g.28034112_28034113insCTTAAGGTCATACTCATACTCCCTAAACCA | c.1809_1810insTTTAGGGAGTATGAGTATGACCTTAAGTGG | p.F594_W603dup | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 F594_W603dup | acute myeloid leukemia | predicted - sensitive | Gilteritinib | Case Reports/Case Series | Actionable | In a clinical study, Xospata (gilteritinib) treatment led to decreased disease burden (<10%) in an acute myeloid leukemia patient harboring FLT3 F594_W603dup (PMID: 33563661; NCT02670525). | 33563661 |